Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 6/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.35 |
| ▸ | KIT | P10721 | 4/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146187 | 1.00 | S1PR3 (0.35) | S1PR3S1PR1KITBDKRB1PDPK1 | |
| SCHEMBL31146144 | 0.81 | KIT (0.36) | S1PR3KITBDKRB1PDPK1PIK3CD | |
| SCHEMBL31145865 | 0.81 | KIT (0.36) | S1PR3KITBDKRB1PDPK1PIK3CD | |
| SCHEMBL31146191 | 0.76 | S1PR3 (0.33) | S1PR3KITBDKRB1PDPK1LRRK2 | |
| SCHEMBL31145872 | 0.76 | S1PR3 (0.33) | S1PR3KITBDKRB1PDPK1LRRK2 | |
| SCHEMBL31146116 | 0.76 | S1PR3 (0.33) | S1PR3KITBDKRB1PDPK1LRRK2 | |
| SCHEMBL31146259 | 0.76 | S1PR3 (0.33) | S1PR3KITBDKRB1PDPK1LRRK2 | |
| SCHEMBL31146015 | 0.76 | S1PR3 (0.36) | S1PR3S1PR1KITPDPK1LRRK2 | |
| SCHEMBL31146066 | 0.75 | PDE9A (0.37) | — | |
| SCHEMBL31146141 | 0.71 | KDM4E (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206339-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | S1PR3 4572/4885S1PR1 4692/4885KIT 4199/4885 |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, COQ8A | S1PR3 4572/4885S1PR1 4692/4885KIT 4199/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | S1PR3 1054/4885S1PR1 1153/4885KIT 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.